Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

BACKGROUND: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs). The...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Clin Risk Manag
Autors principals: Li, Yi, Xie, Yizhao, Gong, Chengcheng, Zhao, Yannan, Zhang, Jian, Zhang, Sheng, Wang, Leiping, Chen, She, Hu, Xichun, Wang, Biyun
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7335268/
https://ncbi.nlm.nih.gov/pubmed/32636632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S255365
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars